1
|
Zhang C, He W, Liu C, Jiao D, Liu Z. Cutting‐edge advancements of nanomaterials for medi‐translatable noninvasive theranostic modalities. VIEW 2021. [DOI: 10.1002/viw.20200144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Affiliation(s)
- Chen Zhang
- Academy of Medical Engineering and Translational Medicine Tianjin University Tianjin China
- Tianjin Key Laboratory of Brain Science and Neural Engineering Tianjin University Tianjin China
| | - Weixin He
- Academy of Medical Engineering and Translational Medicine Tianjin University Tianjin China
- Tianjin Key Laboratory of Brain Science and Neural Engineering Tianjin University Tianjin China
| | - Chenxi Liu
- Academy of Medical Engineering and Translational Medicine Tianjin University Tianjin China
- Tianjin Key Laboratory of Brain Science and Neural Engineering Tianjin University Tianjin China
| | - Dian Jiao
- Academy of Medical Engineering and Translational Medicine Tianjin University Tianjin China
- Tianjin Key Laboratory of Brain Science and Neural Engineering Tianjin University Tianjin China
| | - Zhe Liu
- Academy of Medical Engineering and Translational Medicine Tianjin University Tianjin China
- Tianjin Key Laboratory of Brain Science and Neural Engineering Tianjin University Tianjin China
| |
Collapse
|
2
|
Ostroverkhov P, Semkina A, Naumenko V, Plotnikova E, Melnikov P, Abakumova T, Yakubovskaya R, Mironov A, Vodopyanov S, Abakumov A, Majouga A, Grin M, Chekhonin V, Abakumov M. Synthesis and characterization of bacteriochlorin loaded magnetic nanoparticles (MNP) for personalized MRI guided photosensitizers delivery to tumor. J Colloid Interface Sci 2019; 537:132-141. [DOI: 10.1016/j.jcis.2018.10.087] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2018] [Revised: 10/16/2018] [Accepted: 10/27/2018] [Indexed: 12/27/2022]
|
3
|
Lázár-Molnár E, Delgado JC. Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. Clin Chem 2019; 65:393-405. [DOI: 10.1373/clinchem.2016.266973] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Accepted: 07/10/2018] [Indexed: 12/15/2022]
Abstract
Abstract
BACKGROUND
Monoclonal antibody therapeutics (MATs) represent a rapidly expanding class of biological drugs used to treat a variety of diseases. The widespread use of MATs increasingly affects clinical laboratory medicine.
CONTENT
This review provides an overview of MATs currently approved for clinical use in the US, starting from basic biology of antibodies to the engineering, pharmacokinetic and pharmacodynamic properties, nomenclature, and production of MATs. Immunogenicity and the production of antidrug antibodies (ADAs) play a major role in loss of therapeutic response and the development of treatment failure to certain MATs. Laboratory-based monitoring for MATs and detection of ADAs represent emerging needs for optimizing the use of MATs to achieve the best outcomes at affordable cost. In addition, the increased use of MATs affects clinical laboratory testing by interference of MATs with clinical laboratory tests across different areas of laboratory medicine, including histocompatibility, blood bank, and monoclonal protein testing.
SUMMARY
The number of MATs is rapidly growing each year to address previously unmet clinical needs. Laboratory monitoring of MATs and detecting ADAs represent expanding areas of laboratory testing. Test-based strategies allow for treatment optimization at the level of the individual patient, thus providing a personalized medicine approach. In addition, clinical laboratories must be aware that the increasing use of MATs affects laboratory testing and be ready to implement methods to eliminate or mitigate interference with clinical tests.
Collapse
Affiliation(s)
- Eszter Lázár-Molnár
- ARUP Laboratories, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT
| | - Julio C Delgado
- ARUP Laboratories, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT
| |
Collapse
|
4
|
Ayoub MA, Crépieux P, Koglin M, Parmentier M, Pin JP, Poupon A, Reiter E, Smit M, Steyaert J, Watier H, Wilkinson T. Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges. MAbs 2017; 9:735-741. [PMID: 28475474 DOI: 10.1080/19420862.2017.1325052] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Le STUDIUM conference was held November 24-25, 2016 in Tours, France as a satellite workshop of the 5th meeting of the French GDR 3545 on "G Protein-Coupled Receptors (GPCRs) -From Physiology to Drugs," which was held in Tours during November 22-24, 2016. The conference gathered speakers from academia and industry considered to be world leaders in the molecular pharmacology and signaling of GPCRs, with a particular interest in the development of therapeutic GPCR antibodies (Abs). The main topics were new advances and challenges in the development of antibodies targeting GPCRs and their potential applications to the study of the structure and function of GPCRs, as well as their implication in physiology and pathophysiology. The conference included 2 sessions, with the first dedicated to the recent advances in methodological strategies used for GPCR immunization using thermo-stabilized and purified GPCRs, and the development of various formats of Abs such as monoclonal IgG, single-chain variable fragments and nanobodies (Nbs) by in vitro and in silico approaches. The second session focused on GPCR Nbs as a "hot" field of research on GPCRs. This session started with discussion of the pioneering Nbs developed against GPCRs and their application to structural studies, then transitioned to talks on original ex vivo and in vivo studies on GPCR-selective Nbs showing promising therapeutic applications of Nbs in important physiologic systems, such as the central nervous and the immune systems, as well as in cancer. The conference ended with the consensus that Abs and especially Nbs are opening a new era of research on GPCR structure, pharmacology and pathophysiology.
Collapse
Affiliation(s)
- Mohammed Akli Ayoub
- a PRC, INRA, CNRS, Université François-Rabelais de Tours , Nouzilly , France.,b LE STUDIUM® Loire Valley Institute for Advanced Studies , Orléans , France.,c Biology Department , College of Science, United Arab Emirates University , Al Ain , United Arab Emirates
| | - Pascale Crépieux
- a PRC, INRA, CNRS, Université François-Rabelais de Tours , Nouzilly , France
| | - Markus Koglin
- d Heptares Therapeutics Ltd , BioPark, Welwyn Garden City, Hertfordshire , UK
| | - Marc Parmentier
- e Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles , Brussels , Belgium.,f Welbio, Université Libre de Bruxelles , Brussels , Belgium
| | - Jean-Philippe Pin
- g Institut de Génomique Fonctionnelle (IGF), Université de Montpellier, CNRS UMR5203 , Montpellier , France.,h INSERM U1091 , Montpellier , France
| | - Anne Poupon
- a PRC, INRA, CNRS, Université François-Rabelais de Tours , Nouzilly , France
| | - Eric Reiter
- a PRC, INRA, CNRS, Université François-Rabelais de Tours , Nouzilly , France
| | - Martine Smit
- i Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit , Amsterdam , The Netherlands
| | - Jan Steyaert
- j Structural Biology Brussels, Vrije Universiteit Brussels , Brussels , Belgium.,k Structural Biology Research Center, Vlaams Instituut voor Biotechnologie , Brussels , Belgium
| | - Hervé Watier
- l Université François-Rabelais de Tours, CNRS, UMR 7292 , Tours , France.,m Laboratoire d'Immunologie, CHRU de Tours , Tours , France
| | - Trevor Wilkinson
- n Antibody Discovery and Protein Engineering, MedImmune , Cambridge , UK
| |
Collapse
|